➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
AstraZeneca
Mallinckrodt
Boehringer Ingelheim
Baxter

Last Updated: May 28, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021320


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 021320 describes PLENAXIS, which is a drug marketed by Speciality European and is included in one NDA. Additional details are available on the PLENAXIS profile page.

The generic ingredient in PLENAXIS is abarelix. Additional details are available on the abarelix profile page.
Summary for 021320
Tradename:PLENAXIS
Applicant:Speciality European
Ingredient:abarelix
Patents:0

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INTRAMUSCULARStrength100MG/VIAL
Approval Date:Nov 25, 2003TE:RLD:No

Expired US Patents for NDA 021320

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003   Start Trial   Start Trial
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003   Start Trial   Start Trial
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003   Start Trial   Start Trial
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003   Start Trial   Start Trial
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003   Start Trial   Start Trial
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Baxter
McKesson
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.